All Stories

  1. What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

    Article • Expert Opinion on Pharmacotherapy, November 2018, Taylor & Francis

    Filippo Montemurro

  2. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

    Article • Cancer Medicine, July 2018, Wiley

    Filippo Montemurro, paola berchialla

  3. Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium

    Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

    Filippo Montemurro

  4. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

    Article • The Oncologist, April 2017, Alphamed Press

    Filippo Montemurro

  5. Clinical utility of exemestane in the treatment of breast cancer 

    Article • International Journal of Women s Health, May 2015, Dove Medical Press

    Filippo Montemurro

  6. Biomarkers of drugs targeting HER‐family signalling in cancer

    Article • The Journal of Pathology, December 2013, Wiley

    Filippo Montemurro